Literature DB >> 11850163

Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.

A Speciale1, R Musumeci, G Blandino, I Milazzo, F Caccamo, G Nicoletti.   

Abstract

Moxifloxacin is a new oral 8-methoxy-quinolone with a wide spectrum of activity against Gram-negative and anaerobic bacteria, atypical micro-organisms and multi-resistant Gram-positive bacteria. This study was designed to assess the in vitro activity of moxifloxacin against Gram-positive bacteria with different resistance patterns, anaerobes and atypical micro-organisms such as Chlamydia and Mycoplasma. Moxifloxacin had good activity against Streptococcus pneumoniae with all strains inhibited by < or =0.12 mg/l. The minimal inhibitory concentrations (MICs) of moxifloxacin for Streptococcus pyogenes and Streptococcus agalactiae ranged from 0.03 to 0.5 mg/l while those of ciprofloxacin were about two- to four-fold higher (MICs=0.12-1 mg/l). Moxifloxacin was poorly active against enterococci but its activity against Clostridium and Bacteroides spp. was in the same range as that of metronidazole and superior to that of clindamycin. Moxifloxacin was substantially more active than both ciprofloxacin and sparfloxacin against Chlamydia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850163     DOI: 10.1016/s0924-8579(01)00486-1

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  10 in total

1.  Intravitreal clearance of moxifloxacin.

Authors:  Mohan N Iyer; Feng He; Theodore G Wensel; William F Mieler; Matthew S Benz; Eric R Holz
Journal:  Trans Am Ophthalmol Soc       Date:  2005

2.  Mycoplasma genitalium: should we treat and how?

Authors:  Lisa E Manhart; Jennifer M Broad; Matthew R Golden
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

Review 3.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Efficacy of oral moxifloxacin for aerobic vaginitis.

Authors:  C Wang; C Han; N Geng; A Fan; Y Wang; Y Yue; H Zhang; F Xue
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-11-02       Impact factor: 3.267

5.  Fabrication and Appraisal of Poly (Lactic-Co-Glycolic Acid) - Moxifloxacin Nanoparticles using Vitamin E-TPGS: A Potential Intracanal Drug Delivery Agent.

Authors:  Hardik Makkar; Gaurav Patri
Journal:  J Clin Diagn Res       Date:  2017-06-01

6.  Moxifloxacin in situ gelling microparticles-bioadhesive delivery system.

Authors:  Qiongyu Guo; Ahmed Aly; Oliver Schein; Morgana M Trexler; Jennifer H Elisseeff
Journal:  Results Pharma Sci       Date:  2012-09-25

7.  Investigation of moxifloxacin loaded chitosan-dextran nanoparticles for topical instillation into eye: In-vitro and ex-vivo evaluation.

Authors:  Raad A Kaskoos
Journal:  Int J Pharm Investig       Date:  2014-10

8.  Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections.

Authors:  Anroop B Nair; Jigar Shah; Shery Jacob; Bandar E Al-Dhubiab; Nagaraja Sreeharsha; Mohamed A Morsy; Sumeet Gupta; Mahesh Attimarad; Pottathil Shinu; Katharigatta N Venugopala
Journal:  PLoS One       Date:  2021-03-19       Impact factor: 3.240

9.  Clinical Characteristics of Chlamydia psittaci Pneumonia Infection in Central South China.

Authors:  Min Yang; Dan-Hui Yang; Ping Chen; Hong Luo; Huan Yang; Shui-Zi Ding; Cai-Hong Liu; Hui-Ming Yin; Dan Liu
Journal:  Infect Dis Ther       Date:  2022-06-20

10.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.